32
Figure 10. Systemic Therapy for Patients with Ovarian Cancer
(All Stages)
Patients with ovarian cancer who received surgery
Patients with stage I ovarian cancer
Patients with
early-stage ovarian
borderline or LMP
tumors or early-
stage micro-invasive
borderline tumors
Should not
administer
adjuvant
chemotherapy
Patients with
surgically staged,
pathologic
confirmed
epithelial, ovarian,
fallopian tube, or
peritoneal cancer
Patients in
whom pathology
confirmation
not possible,
but cytologic
confirmation, CA-
125 and imaging
Access pre-treatment
to determine patient's
eligibility for adjuvant
chemotherapy
Patients with stage
I ovarian cancer,
not low-risk stage
IA/B Grade 1
Patients fit for
combination therapy
Patients unfit for
combination therapy
Combination
chemotherapy
with paclitaxel and
carboplatin
Single-agent
chemotherapy
Single-agent
carboplatin
chemotherapy is an
option
Customize
tolerability, etc.,
to patient for a
minimum of 6 cycles
Optimum number
of 6 cycles of
chemotherapy in the
adjuvant setting
Clinicians may refer
to higher-level cancer
center for adjuvant
chemotherapy
Treatment
